Skip to Main Content

Author Details

Channing J Paller
Johns Hopkins University School of Medicine
2004
99
31
PMIDPaper TitleJournal TitlePublished Year
38050021Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.Cold Spring Harb Mol Case Stud2024
37964482PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.Prostate2024
38070485Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.JNCI Cancer Spectr2024
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
38064163The ENGAGE study: evaluation of a conversational virtual agent that provides tailored pre-test genetic education to cancer patients.J Cancer Surviv2023
37582238Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline.J Clin Oncol2023
36993449PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.bioRxiv2023
36860652Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.Cancer Res Commun2023
35013522Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.Prostate Cancer Prostatic Dis2022
35503984Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.Am Soc Clin Oncol Educ Book2022
35500949Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.Value Health2022
35446628Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).J Clin Oncol2022
36648953Analytical Validation of <i>SOD2</i> Genotyping.Methods Protoc2022
35875156Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review.Front Oncol2022
36212797A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer.Kidney Cancer2022
36001857Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.J Clin Oncol2022
36171797Applications for open access normalized synthesis in metastatic prostate cancer trials.Front Artif Intell2022
35928859Editorial: Big Data and machine learning in cancer theranostics.Front Big Data2022
35985011The Society for Integrative Oncology: Two Decades of Global Leadership in Evidence-Based Integrative Health Care.J Integr Complement Med2022
33830214Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.J Natl Cancer Inst2022
32536574Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.Eur Urol Oncol2021
33852088The Society for Integrative Oncology Practice Recommendations for online consultation and treatment during the COVID-19 pandemic.Support Care Cancer2021
33617303TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.J Clin Oncol2021
33535682Val16A SOD2 Polymorphism Promotes Epithelial-Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells.Antioxidants (Basel)2021
34440246<sup>177</sup>Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Biomedicines2021
34516663Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.Prostate2021
33964161The Realities of Prostate Cancer Screening, Treatment, and Race.J Natl Cancer Inst2021
33983407Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer-Reply.JAMA Oncol2021
34310190Payer Coverage of Integrative Medicine Interventions for Symptom Control in Patients With Cancer.JCO Oncol Pract2021
33419682The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Eur Urol2021
33443584Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.JAMA Oncol2021
33383350Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.Eur J Cancer2021
32798608Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2021
32572471Overdiagnosis in the Age of Digital Cancer Screening.J Natl Cancer Inst2021
32624280A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.Eur Urol2021
31176623Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Eur Urol2020
33233320Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel)2020
32986533Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.JCO Oncol Pract2020
32528098Author Correction: Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations.Sci Rep2020
32215577Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA Oncol2020
32466595PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.Cancers (Basel)2020
32435466Relationship of sex steroid hormones with bone mineral density of the lumbar spine in adult men.Bone Joint Res2020
32139709Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations.Sci Rep2020
32487038A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).BMC Cancer2020
32483272Measuring Cancer Hallmark Mediation of the TET1 Glioma Survival Effect with Linked Neural-Network Based Mediation Experiments.Sci Rep2020
31131348Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.JCO Precis Oncol2019
31933562Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted <sup>18</sup>F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.World J Nucl Med2019
30155899TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.Prostate2019
31530439PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.Clin Genitourin Cancer2019
31214592Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials.Front Med (Lausanne)2019
  • 1 - 50 of 99

Recommended Authors

Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 1
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 8
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 20
Roberta Ferraldeschi
Astex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 15
Niven Mehra
Radboud university medical center
Career Start Year 2004
Number of shared co-authors 19
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 26
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Career Start Year 2003
Number of shared co-authors 29
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 26
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 10
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 30
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 20
Michael J Morris
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 31
Johann S de Bono
The Institute for Cancer Research
Career Start Year 1999
Number of shared co-authors 32
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 5
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 14
Todd M Morgan
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 35
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 26
Stephen J Freedland
Cedars-Sinai Medical Center
Career Start Year 1996
Number of shared co-authors 36
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 17
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 26
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 12
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 37
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 25
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 20
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 27
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 12
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 42
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 39
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 34
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 32

Collaborators

Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 39
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 37
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 32
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 12
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 11
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 11
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 10
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 10
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 10
Curtiland Deville
Johns Hopkins University
Co-authored papers 10
Ryan Phillips
Johns Hopkins University
Co-authored papers 9
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 9
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Co-authored papers 6
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 6
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Thomas Luechtefeld
Co-authored papers 5
Ashley E Ross
Northwestern University
Co-authored papers 5
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 4
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 4
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Co-authored papers 4
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 4
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 4
Bruce J Trock
Johns Hopkins University School of Medicine
Co-authored papers 3
Bradley J Stish
Mayo Clinic
Co-authored papers 3
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers 3
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 3
George Caleb Alexander
Institute of General Practice and Family Medicine, University Hospital
Co-authored papers 3
Jake Vinson
Prostate Cancer Clinical Trials Consortium (PCCTC)
Co-authored papers 3
Neil B Desai
University of Texas Southwestern Medical Center
Co-authored papers 3
Ben Ho Park
Vanderbilt University Medical Center
Co-authored papers 2
Release 1.2